Journal Watch

Thrombotic microangiopathies

Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era.
Author(s): Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M
Source: Nephron 2020;144(11):537-549
Publication date: 2020
Thrombotic microangiopathy: COVID-19 or hydroxychloroquine?
Author(s): Hasbal NB
Source: Kidney Int 2020 Dec;98(6):1619-1620
Publication date: 2020-12
Thrombotic microangiopathy and their mimickers.
Author(s): Palma LMP, Sethi S
Source: Nephrol Dial Transplant 2020 Sep 23;
Publication date: 2020-09-23
Eculizumab, SARS-CoV-2 and atypical hemolytic uremic syndrome.
Author(s): Trimarchi H, Gianserra R, Lampo M, Monkowski M, Lodolo J
Source: Clin Kidney J 2020 Oct;13(5):739-741
Publication date: 2020-10
Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation.
Author(s): Mezö B, Horváth O, Sinkovits G, Veszeli N, Kriván G, Prohászka Z
Source: Front Med (Lausanne) 2020;7:569291
Publication date: 2020
+ Show 97 more...


To register for the JWatch Subscription, you must accept cookies

European Reference Networks
ERKNet is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission.
For more information about the ERNs and the EU health strategy, please visit http://ec.europa.eu/health/ern